Ac
Achilles Therapeutics
London UKFounded 2016100 employees
Private CapbiotechAcquiredOncology
Platform: Clonal Neo-Ag
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pemiosocimab | ACH-2429 | Phase 1 | 2 | PD-L1 | CF | ||
| Ivocapivasertib | ACH-6170 | Phase 1 | 2 | FLT3 | Endometrial CaFTD | ||
| Bemasertib | ACH-3903 | Phase 1 | 2 | PLK4 | DravetCholangiocarcinoma | ||
| Voxazanubrutinib | ACH-6430 | Phase 1/2 | 2 | PCSK9 | MigraineObesity |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)